
Shares of telehealth platform Mangoceuticals MGRX.O rise 43% to 51 cents premarket
Co says its new $99/month injectable testosterone therapy plan saw sales jump 336% month‑over‑month since mid‑December
MGRX says it also cut its customer acquisition costs by more than half
Mangoceuticals expects testosterone therapy to become its main growth driver
In 2025, MGRX plunged 70%